Financial Performance - Net Revenues increased by 2.6% to $255 million, or 4.4% on a constant currency basis[39, 34] - Adjusted EBITDA increased by 8.8% to $122 million, or 11.2% on a constant currency basis[39, 34] - Adjusted EBITDA margin expanded by 276 basis points to 47.9%[34, 39] - Adjusted EPS increased by $0.01 to $0.14[34, 39] Segment Performance - Sterigenics revenue increased by 1.9% to $170 million, with a segment income increase of 2.5%[43] - Nordion revenue increased by 35.6% to $33 million, with a segment income increase of 61.5%[47] - Nelson Labs revenue decreased by 9.3% to $52 million, but segment income increased by 7.0%[51] Liquidity and Capital Deployment - Strong liquidity position of $715 million as of March 31, 2025, with no outstanding borrowings on the revolving line of credit[36, 55] - Net Leverage Ratio improved to 3.6x as of March 31, 2025[36, 57] - Completed $176 million upsize of the revolving line of credit and extended the facility to April 2030[36, 61] 2025 Outlook - The company expects Net Revenues to increase by 4.0% to 6.0%[64] - The company expects Adjusted EBITDA to increase by 4.5% to 6.5%[64]
Sotera Health(SHC) - 2025 Q1 - Earnings Call Presentation